Meeting
2024 ASCO Annual Meeting
Detection of comprehensive oncogenic driver alteration of non-small cell lung cancer from cytology specimens by multi-gene PCR panel.
Authors
Tetsuya Sakai
National Cancer Center Hospital East, Kashiwa, Japan
Tetsuya Sakai , Hiroki Izumi , Shingo Matsumoto , Hibiki Udagawa , Yu Tanaka , Eri Sugiyama , Shigeki Umemura , Yoshitaka Zenke , Kiyotaka Yoh , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8579)
DOI
10.1200/JCO.2024.42.16_suppl.8579
Abstract #
8579
Poster Bd #
443
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.
First Author: Alexander Watson
Poster
2023 ASCO Annual Meeting
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
First Author: Alissa Jamie Cooper
Poster
2023 ASCO Annual Meeting
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).
First Author: Christine M. Bestvina
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox